Suppr超能文献

相似文献

2
MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.
Am J Respir Cell Mol Biol. 2004 Jul;31(1):86-91. doi: 10.1165/rcmb.2003-0345OC. Epub 2004 Feb 26.
3
MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation.
Am J Respir Crit Care Med. 2007 Apr 15;175(8):816-21. doi: 10.1164/rccm.200607-1011OC. Epub 2007 Jan 25.
4
Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure.
J Clin Invest. 2014 Jul;124(7):3047-60. doi: 10.1172/JCI73469. Epub 2014 Jun 2.
5
Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis.
J Cyst Fibros. 2022 Nov;21(6):959-966. doi: 10.1016/j.jcf.2022.04.008. Epub 2022 Apr 16.
6
Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis.
Am J Respir Crit Care Med. 2020 Mar 15;201(6):661-670. doi: 10.1164/rccm.201906-1219OC.
8
IL-1β dominates the promucin secretory cytokine profile in cystic fibrosis.
J Clin Invest. 2019 Oct 1;129(10):4433-4450. doi: 10.1172/JCI125669.
9
Gel-forming mucins form distinct morphologic structures in airways.
Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):6842-6847. doi: 10.1073/pnas.1703228114. Epub 2017 Jun 12.

引用本文的文献

1
The effect of modulators on lung function following inpatient treatment for CF exacerbations.
Front Pediatr. 2025 Aug 21;13:1654122. doi: 10.3389/fped.2025.1654122. eCollection 2025.
2
Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target.
Eur Respir J. 2025 Sep 17;66(3). doi: 10.1183/13993003.00081-2025. Print 2025 Sep.
3
Sputum quality affects assessment of airway microbiology in childhood asthma.
Respir Res. 2025 Jun 4;26(1):209. doi: 10.1186/s12931-025-03266-x.
4
Macroheterogeneities Induced by Disulfide Bond Reduction in Native Mucus.
ACS Appl Bio Mater. 2025 Jun 16;8(6):4647-4656. doi: 10.1021/acsabm.4c01758. Epub 2025 May 19.
6
Modulation of pulmonary immune functions by the secondary metabolite pyocyanin.
Front Immunol. 2025 Mar 24;16:1550724. doi: 10.3389/fimmu.2025.1550724. eCollection 2025.
7
pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against .
Antimicrob Agents Chemother. 2025 May 7;69(5):e0153524. doi: 10.1128/aac.01535-24. Epub 2025 Mar 26.
8
Biopolymeric Inhalable Dry Powders for Pulmonary Drug Delivery.
Pharmaceuticals (Basel). 2024 Dec 4;17(12):1628. doi: 10.3390/ph17121628.
9
Rheological comparison of sputum and reconstituted airway epithelium mucus.
Sci Rep. 2024 Dec 30;14(1):31660. doi: 10.1038/s41598-024-80932-y.

本文引用的文献

3
Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis.
Am J Respir Crit Care Med. 2020 Mar 15;201(6):661-670. doi: 10.1164/rccm.201906-1219OC.
4
Roles of mucus adhesion and cohesion in cough clearance.
Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12501-12506. doi: 10.1073/pnas.1811787115. Epub 2018 Nov 12.
6
Localization of Secretory Mucins MUC5AC and MUC5B in Normal/Healthy Human Airways.
Am J Respir Crit Care Med. 2019 Mar 15;199(6):715-727. doi: 10.1164/rccm.201804-0734OC.
7
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18.
8
Filter-Aided Sample Preparation for Proteome Analysis.
Methods Mol Biol. 2018;1841:3-10. doi: 10.1007/978-1-4939-8695-8_1.
9
An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.
Am J Respir Crit Care Med. 2019 Jan 15;199(2):171-180. doi: 10.1164/rccm.201802-0245OC.
10
Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.
Eur Respir J. 2018 Jul 11;52(1). doi: 10.1183/13993003.00242-2018. Print 2018 Jul.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验